Biointelect Venturer

Funding Guidelines

Round 2

September 2026

Table of Contents

Acronyms

AI – Artificial Intelligence
ABN – Australian Business Number
ACN – Australian Company Number
ATO – Australian Taxation Office
AUD – Australian Dollar
BMTI – BioMedTech Incubator
CAG – Consumer Advisory Group
CMC – Chemistry, Manufacturing and Controls
CRO – Contract Research Organisation
EOI – Expression of Interest
FTE – Full-Time Equivalent
GMP – Good Manufacturing Practice
IND – Investigational New Drug
IP – Intellectual Property
IRC – Investment Review Committee
MRFF – Medical Research Future Fund
NIH – National Institutes of Health
PPE – Personal Protective Equipment
SaMD – Software as a Medical Device
SME – Small-to-Medium Enterprise
TPP – Target Product Profile
TRL – Technology Readiness Level

1 About Biointelect Venturer

1.1 About Biointelect Venturer

Biointelect Venturer is Australia's national incubator for infectious disease innovation, helping promising Australian small to medium enterprises (SMEs) translate science into viable health technologies and deliver meaningful public health impact.

Biointelect Venturer was launched in 2025 and has been established with $32.9 million in funding from the Australian Commonwealth Government under the Medical Research Future Fund (MRFF) 2024 BioMedTech Incubator Grant Opportunity. Under the 2024 grant, Biointelect Venturer will deliver two national funding rounds/incubator intakes and one top-up funding round for high-potential projects that were funded during Round 1 and 2.

Round 1 funding and incubator intake has been completed. Awardees for Round 1 were announced on 31st August 2026 – details are available here. The information contained in this document pertains to Round 2.

The Biointelect Venturer incubator program combines catalytic non-dilutive funding with tailored commercialisation support, strategic guidance, mentoring, market orientation, milestone-based project management, engagement and access to national and international stakeholder, funding and investor networks. This integrated model helps innovators de-risk development, strengthen product development and commercialisation strategies, meet regulatory, funder and investor expectations, and increase investment readiness.

By connecting expertise, partnerships and infrastructure across Australia's vaccine and biotech ecosystem, Biointelect Venturer aims to bridge the research translation and commercialisation gap and become a catalyst for transformative Australian infectious disease innovation.

www.biointelect.com/biointelect-venturer

1.2 About Biointelect

Biointelect Venturer is managed and operated by Biointelect, enabling it to leverage Biointelect's deep expertise and success in supporting early-stage biotech and medtech commercialisation.

Biointelect is a globally recognised Australian company offering a unique blend of full-service Contract Research Organisation (CRO) and life sciences consulting services including regulatory and commercialisation expertise and capability. With deep roots across the health innovation ecosystem, Biointelect provides end-to-end support across the entire development pathway from early-stage research through to market access and health system integration.

www.biointelect.com

2 Biointelect Venturer – Round 2

2.1 Round 2 Funding Details

Funding is tailored to the Technology Readiness Level (TRL) and needs of each project to support pre-clinical and clinical product development and commercialisation activities.

Funding available to eligible applicants for Round 2:

- **Applicants at TRL 3 to 4:** eligible for up to AUD 1.5 million.
- **Applicants at TRL 5 to 6:** eligible for up to AUD 3 million.
- *Projects at TRL 2 may be considered in exceptional cases, if they are about to progress to TRL 3 or have a credible plan to achieve TRL 4 within the Biointelect Venturer funded project period. These exceptional TRL 2 cases will be eligible for up to AUD 1.5 million.*

Table 1: Overview of Technology Readiness Levels (TRLs; adapted from the National Institutes of Health (NIH) Centers for Accelerated Innovations)

Technology Readiness Levels (TRL)							
1	2*	3	4	5	6	7	8
Review of Scientific Knowledge Base	Development of Product Hypothesis	Identification and Characterisation of Product Candidate	Optimisation and Initial Demonstration of Safety and Efficacy	Advanced Characterisation of Product and Initiation of Manufacturing	Regulated Production, Regulatory Submission, and Clinical Data (Phase I Clinical Trials)	Scale-up, Initiation of GMP Process Validation, and Phase II Clinical Trials	Completion of GMP Validation and Consistency Lot Manufacturing, Phase III Clinical Trials
Discovery Research and Idea Generation		**Preclinical Testing and Feasibility**			**Early Clinical Studies and Product Development**	**Late Clinical Studies and Evidence Building**	
Not eligible		**Eligible**				**Not eligible**	

*Projects at TRL 2 may be considered in exceptional cases if they are about to progress to TRL 3 or have a credible plan to achieve TRL 4 within the Biointelect Venturer funded project period.

Funding structure

Successful SMEs will have up to 20 months to complete project activities agreed as part of the application and selection process. Funding will be released in tranches aligned to commercially relevant milestones and the successful navigation of agreed Go/No-Go points.

Given that funding is milestone-based, SMEs that do not meet milestones in their development program may not continue to receive funding.

Subject to project performance and funding availability, selected SMEs may be eligible to apply for additional top-up funding. Top-up funding eligibility will be subject to satisfactory achievement of agreed milestones and Go/No-Go points, a competitive assessment process and the relevant governance approvals. The total funding awarded to an individual project across the program will not exceed AUD 5 million, as per MRFF funding guidelines.

Examples of activities that Biointelect Venturer funding may support include:

- Product development and strategy (including Target Product Profile development)
- GMP manufacturing and process development including assay development, technology transfer and scale up activities
- Portfolio prioritisation and market assessments
- Business planning
- Funding and investment strategy development
- Regulatory authority and safety studies supporting first-time-in-human studies ('IND-enabling') e.g. non-clinical toxicology; Chemistry Manufacturing Controls (CMC)
- Investigator's Brochure preparation
- Regulatory strategy and submissions
- Early-phase clinical studies

See Appendix 1 for further details on eligible and ineligible expenditures.

2.2 Round 2 Key Dates

Table 2: Key dates for Round 2

Round 2 Activities	Dates
EOI opening period	21 September 2026, 9:00 AM AEST to 16 October 2026, 4:00 PM AEDT
Information session	24 September 2026 at 11:00am (AEST)
Grant Writing workshop	30 September 2026 at 11:00am (AEST)
EOI outcomes	Mid-February 2027
Full applications open	Mid-February 2027
Full applications close	Mid-March 2027
Interviews	Early May 2027
Full application outcomes	Late May 2027
Contracting	Late May 2027 to late July 2027
Onboarding and Project commencement	Late July 2027

3 Eligibility Criteria

3.1 Technology Eligibility

The Biointelect Venturer program focuses on innovations for the **prevention** of infectious diseases, that address high unmet clinical needs and/or have clear global or regional health-security benefit and show strong commercialisation potential.

Eligibility – Areas of focus

- The technology's lead indication must directly address the **prevention** of a defined infectious disease in humans.
- Technologies for the management or treatment of another condition that directly or indirectly affects infection risk are **not** in scope.
- Projects aimed at the treatment or management, i.e. preventing progression of established disease, without a preventative component, are **ineligible**.

- Technologies targeting zoonotic and vector-borne diseases, or cancers caused by infectious agents, are considered **eligible** only where the proposed technology is intended for direct use in humans.

Eligibility – Modalities

Modalities eligible for Round 2 of Biointelect Venturer include:

- Prophylactic vaccines
- Prophylactic therapeutics, direct and indirect
    - Direct: therapeutics that directly target, bind to, or neutralise the pathogen itself (e.g. preventative monoclonal antibodies)
    - Indirect: host-directed therapeutics that target human host cells or the immune system, rather than the pathogen itself, to prevent establishment of infection (e.g. biologics or small molecules that block human cell entry receptors or prime the human immune system)
- Vaccine platform and enabling technologies
    - Technology platforms that support the development of multiple preventative vaccines or therapeutics products targeting different pathogens
    - Technologies that could meaningfully enable or enhance vaccine or prophylactic therapeutic efficacy or delivery, and can be applied across a range of pathogens with a direct translation product pathway (e.g. adjuvants, liquid nanoparticle technologies, molecular or structural stabilising factors engineered directly into the antigen construct)

The following modalities will **not** be eligible for this funding round:

- Diagnostics
- Devices (e.g. delivery systems)
- Therapeutic interventions intended primarily to treat existing infections, progression of infection or diseases
- Host-directed therapies that reduce symptoms after infection onset
- Artificial Intelligence (AI) and digital health tools
- Software as a medical device (SaMD)
- Interventions which act as an anti-infective e.g. topical antiseptics or surface disinfectants.

Eligibility - Stage of development

- Technologies must be at TRL 3-6 at the time of application.
- Projects at TRL 2 may be considered in exceptional cases, if they are about to progress to TRL 3 or have a credible plan to achieve TRL 4 within the Biointelect Venturer funded project period. Projects more advanced than TRL 6 are out of scope.
- For vaccine platform and enabling technologies, it is acknowledged that the stage of development and thus TRL of the lead indication or product utilising the platform or enabling technology may differ to that of the broader underlying platform or enabling technology. A difference in TRL in this scenario does not in itself deem the technology ineligible for Biointelect Venturer. Final eligibility will be determined by Biointelect Venturer following assessment of the Expression of Interest (EOI).

3.2 Applicant Eligibility

To be eligible for the Biointelect Venturer incubator, applicants must:

- Be an Australian SME (i.e. a registered Australian corporate entity [1] with an ABN employing no more than 199 employees); or
- Be a researcher at an Australian University or Medical Research Institute that will commit to incorporating a new company that meets the above SME requirements **prior** to award of funding. **Biointelect Venturer funding will not cover the cost of company formation or incorporation.** Any expenses related to establishing a new entity, such as legal, accounting or administrative fees, must be borne by the applicant or their host institution.
- Provide a letter of support from their Board/Executive leadership (for established companies) or Business Development Manager/Tech Transfer office (for researcher-led applicants at Australian-based Universities and Medical Research Institutes).

Not-for-profit enterprises are eligible to apply provided they meet the other eligibility criteria, including demonstrating a clear pathway to commercialisation.

Large companies with over 200 employees, unincorporated entities, sole traders, and companies registered outside Australia are not eligible.

Multiple applications

Each SME may submit only one application under this funding round. Universities, Medical Research Institutes, and other publicly funded research organisations may put forward more than one proposal, provided each relates to a distinct project related to one company. Where multiple

[1] https://www.asic.gov.au/for-business-and-companies/business-basics/

submissions are coordinated by the same organisation, every project and associated company must be clearly differentiated and, where relevant, include its own ABN or ACN.

Australian Operations and local activity

Biointelect Venturer funding is intended to support translation, development and commercialisation of local innovation from Australian SMEs that are registered in Australia and operate primarily within the Australian innovation ecosystem.

An Australian-incorporated subsidiary of an international company may be eligible, provided:

- It is a registered incorporated Australian entity with an ABN
- It employs fewer than 200 staff
- It conducts substantive project activities in Australia
- Intellectual Property (IP) ownership for the technology resides in Australia

However, subsidiaries that act primarily as sales, distribution, or administrative offices for overseas parent companies, or where decision-making and IP ownership reside offshore, are not eligible.

3.3 Intellectual Property Eligibility

Applicants must hold or secure transferable rights to any required background IP, with access on commercial terms for market entry.

Applicants applying prior to incorporation must demonstrate a credible plan to secure and transfer required IP to the new entity before execution of the funding agreement. To ensure feasibility of the plan, applicants' licensor(s) must execute a written undertaking granting applicants the right to secure transferable rights to any required background IP on commercial terms, subject only to the grant being awarded and the venture being incorporated.

Identification of potentially blocking third-party IP, e.g., potentially relevant pending claims found in third-party patent applications, does not deem the funding application ineligible, but may lead to a specific risk assessment by Biointelect Venturer.

Biointelect Venturer does not seek or retain ownership of any IP arising from or associated with funded projects. All IP remains with the participating organisation or company.

Applicants are encouraged to use the decision tree in Figure 3 below to help determine whether their application meets the IP eligibility requirements for the Biointelect Venturer program.

Figure 3: Intellectual property eligibility decision tree



Biointelect Venturer may request further IP analysis or supporting evidence during due diligence where material third-party IP risks are identified. This may include an appropriately scoped freedom-to-operate assessment where warranted. Any material IP risks must be sufficiently understood and capable of being appropriately managed before a funding agreement is executed.

This decision tree provides preliminary guidance only. Biointelect Venturer does not provide IP advice. Applicants should seek independent advice where appropriate.

* Contact venturer@biointelect.com for enquiries

4 Application Process

4.1 Governance and Evaluation Committees

The Biointelect Venturer application and selection process includes expert review and recommendation by the Biointelect Venturer **Investment Review Committee** (IRC). The IRC is an independent committee, composed of internationally and nationally recognised experts with deep expertise spanning vaccine and therapeutic product development, infectious diseases, pre-clinical and clinical development, regulatory affairs, and manufacturing and process development. IRC members also bring substantial experience in local and international funding, investment, market access, commercialisation and intellectual property management.

IRC recommendations are reviewed and endorsed by the Biointelect Venturer Steering Committee. The Steering Committee is an independent, nationally representative advisory group that provides expert advice on the operations of the incubator under the terms of the Commonwealth Agreement and MRFF award to the Biointelect Board. All IRC and Steering Committee recommendations and endorsements are reviewed for approval by the **Biointelect Board**.

The **Consumer Advisory Group (CAG)**, consisting of 10-12 consumers from diverse backgrounds, provides a complementary perspective within the incubator's governance framework by ensuring that consumer and community views inform program design and decision-making.

All advisory group and committee members are appointed under Biointelect's Confidentiality and Conflict-of-Interest Policy. Any real or perceived conflicts are declared and managed to ensure a fair, transparent, and unbiased review and decision-making process.

4.2 Application & Selection Process

The Biointelect Venturer application and selection process ensures a rigorous and independent assessment through a structured multi-stage framework.

Figure 4: Round 2 application and selection process



Phase 1: Expressions of Interest (EOI)

Applicants must submit a non-confidential EOI through the Biointelect Venturer application portal addressing the published selection criteria (Table 5). EOIs will be screened for eligibility by the Biointelect Venturer team.

Phase 2: Targeted Due Diligence

Eligible EOIs will undergo a targeted due diligence review by the Biointelect Venturer team on relevant technical, clinical, regulatory and commercial aspects of the technology. EOIs and associated due diligence outputs will be assessed by the IRC against defined selection criteria and ranked accordingly.

Shortlisted EOIs, confirmed through the post-evaluation IRC calibration process, are submitted for endorsement by the Biointelect Venturer Steering Committee and approval by the Biointelect Board, before being invited to progress to Phase 3 and submit a full application.

Phase 3: Full Application

Approved shortlisted applicants will be invited to prepare and submit a full application that expands on the EOI, and addresses any feedback received during the EOI process, to provide a more comprehensive outline of the technology and proposed project.

The IRC, with input from the CAG and technical experts where required, will assess full applications against defined selection criteria and ranked accordingly.

Shortlisted applicants will be invited to participate in an interview with a panel comprising of representatives of the Biointelect Venturer team, the IRC and Steering Committee, where applicants will have an opportunity to respond to specific questions that may have arose during the assessment process.

Phase 4: Final Selection and Award

Outputs from the applicant interviews inform the final recommendations for funding, which are submitted for endorsement to the Steering Committee and subsequently reviewed and approved by the Biointelect Board prior to award and contracting.

Competitive Assessment

Biointelect Venturer is a competitive funding program. Eligible applications will be assessed on their merits against the published selection criteria. In assessing applications, the relevant assessment bodies will consider:

- How well the application addresses the selection criteria;

- How the application compares with other eligible applications received in the funding round; and
- The overall value, risk and potential impact of the proposed project.

Meeting the eligibility requirements or satisfactorily addressing the selection criteria does not guarantee progression or funding. Funding decisions will also consider the relative competitiveness of applications and the funding available for the round.

Funding Decisions

Biointelect Venturer funding decisions are final. Applicants may raise concerns regarding the administration or integrity of the assessment process; however, disagreement with the assessment of the merits of an application does not provide a basis for reassessment or review of the funding decision.

4.3 Selection Criteria

The selection criteria outlined in Table 5 are used to assess applications and identify technologies demonstrating strong impact, scientific merit, clinical relevance, and commercialisation potential. Applicants are encouraged to refer to these criteria as guidance when preparing their applications.

While these criteria are used to guide application assessment, addressing them does not guarantee progression through the application process or funding. The selection criteria will be used to assess relative competitiveness against other eligible applications received in the funding round, rather than to simply determine whether an application meets a minimum threshold.

Table 5: Selection criteria

Criteria	Weighting	What Biointelect Venturer looks for in applications
Unmet need and impact	20%	A proposed solution that is novel, differentiated and addresses a clearly defined public health or clinical unmet (or underserved) need. Clear articulation of the solution's value proposition, how it could deliver meaningful population-level and/or market impact and clear competitive advantage or differentiation from current standard of care, solutions available or solutions in development.
Scientific and technical merit	25%	A robust scientific rationale, clearly articulating and validating the mechanism of action of the intervention and data confirming the intervention is effective in pre-clinical models. Supportive data that demonstrate

		feasibility, reproducibility, and potential for production at scale.
Project plan	15%	A well-defined, milestone-driven project plan that aligns with the critical path towards the next key value inflection point and the broader path to market. Proposed activities are supported and justified by measurable deliverables, clear Go/No-Go decision points, identification of key risks and associated mitigation strategies, realistic timelines, and an appropriate, justified budget aligned with project scope and stage of development.
Translation and commercialisation	25%	A credible translation, development and commercialisation plan and path to market covering a follow-on funding/investment strategy, plans for partnerships/collaborations and a realistic strategy to advance to the next stage of development, TRL and/or value inflection point. Together with an appropriate regulatory pathway, favourable IP position and justified target market, there is evidence of a clear commercial and/or commercialisation opportunity. While some infectious disease interventions may hold uncertain commercial return, a clear mechanism and pathway to commercialisation must be evident.
Team capability and resources	15%	A committed, multidisciplinary and diverse team with the required track-record, expertise, resources, and access to required infrastructure or partners to achieve the proposed milestones and objectives of the proposed project and ultimately, position the technology as an attractive opportunity for follow-on investment.

4.4 Applicant Support

To support prospective applicants, Biointelect Venturer will host an online **Information Session** and **Grant Writing Workshop**. Following the live sessions, a recording will be made available on the Biointelect Venturer website.

Applicants are encouraged to attend both these webinars or view the recordings to assist with determining eligibility and to strengthen applications.

Round 2 Information Session

- **Date:** Thursday, 24 September 2026
- **Time:** 11:00 am AEST
- **Location: Online**

This session aims to introduce the program, outline eligibility criteria for Round 2, explain the application and selection process, and provide prospective Round 2 applicants with an opportunity to ask questions and clarify requirements for the EOI.

Grant Writing Workshop

- **Date:** Wednesday, 30 September 2026
- **Time:** 11:00 am AEST
- **Location: Online**

New for Round 2, Biointelect Venturer will host a grant writing workshop for prospective applicants. The workshop is intended as an additional capability-building activity to help applicants better understand the application requirements and strengthen the quality of their applications ahead of the EOI opening period.

The workshop also aims to build capability beyond the projects ultimately funded through Biointelect Venturer by supporting the broader ecosystem of innovations for infectious disease prevention.

Frequently Asked Questions (FAQs)

Please refer to the FAQs listed on the Biointelect Venturer website here, for additional guidance. This page will be regularly updated as additional FAQs are received throughout the Round 2 application period.

Applicant Enquiries

Please direct all enquiries to the Biointelect Venturer mailbox (venturer@biointelect.com). This mailbox is monitored during business hours to ensure that applicant enquiries are addressed promptly. The Biointelect Venturer team will aim to respond to all enquiries within three (3) business days.

To ensure equal access to information, Biointelect Venturer may publish de-identified questions and responses from potential applicants on the program website **FAQs** page. If your enquiry contains confidential information, please clearly indicate this in your correspondence, so it is not shared publicly.

Biointelect Venturer accepts no responsibility for the disclosure of information submitted outside the formal application process unless it has been expressly marked as confidential. In all cases, Biointelect Venturer will not disclose the identity of the organisation or individual submitting a question.

5 Contact Information

For more information about Biointelect Venturer visit: www.biointelect.com/biointelect-venturer

For any enquiries, please contact venturer@biointelect.com

6 Appendices

Appendix 1: Biointelect Venturer eligible use of funds

All funding provided through Biointelect Venturer must comply with the 2024 Medical Research Future Fund (MRFF) BioMedTech Incubator (BMTI) Grant Opportunity Guidelines on eligible expenditure.

Funding will only be used for approved project activities as defined in the executed funding agreement between the SME and Biointelect. If your application is successful, you may be required to provide evidence, such as quotes for major project costs.

Not all expenditure on your project may be eligible for grant funding. To be eligible, expenditure must be a direct cost of the project or be incurred by you for required project audit activities. All costs must be incurred within the agreed project period unless otherwise specified.

Eligible and ineligible expenditure is outlined below (adapted directly from the MRFF BMTI Grant Opportunity Guidelines). For clarification on whether specific costs meet eligibility requirements, applicants are encouraged to contact the Biointelect Venturer team prior to submission.

Eligible Expenditure

Equipment

- Funding may be used to purchase equipment that is essential to achieving project objectives and outcomes.
- Applicants must justify why each item is critical to the proposed research and why it cannot be accessed through existing institutional resources.

- Applicants can request funding for equipment costing over AUD 10,000 that is essential to the research. The total equipment cost requested must not exceed 5% of the total grant amount up to a maximum of AUD 80,000.
- Applicants must be prepared to cover all service, maintenance, and repair costs for funded equipment.
- Computers are not eligible unless they are integral to specialised laboratory equipment or essential for processing large scientific datasets.
- Requests must include:
    - the purpose and use of each item,
    - its estimated cost, and
    - an explanation of why institutional equipment cannot be used.

Labour expenditure

- Direct labour costs of employees working on the core project activities. Labour costs must relate to personnel directly employed by the applicant and paid a regular salary or wage with standard tax deductions.
- Eligible roles may include technical, scientific, administrative, and project management staff**,** where there is a clear and measurable link to project objectives.
- Labour costs for leadership or administrative roles (e.g. CEO, CFO) are eligible up to 10% of total labour expenditure.
- The maximum claimable salary for any individual (including packaged components) is AUD 175,000 per annum. Salary claims must be pro-rated for project periods shorter than one year. Salary costs can only be claimed for time directly spent on project activities during the approved project period. There needs to be an auditable record of time spent on the project.
- Commonwealth-funded positions can be considered eligible to count towards an in-kind contribution. However, the Commonwealth-funded position cannot also draw a salary from funds awarded through this grant opportunity for the same activity.
- You may include eligible salary costs (on-costs) such as employer paid superannuation, payroll tax, workers compensation insurance, and leave entitlements (including paid maternity leave, sick leave, long service leave and recreation leave). These costs must be reasonable and be separately identified in the project budget. On-costs are considered separate and are not included as part of the salary cap.
- You should calculate eligible salary costs using the formula below:

$$\text{Eligible salary costs} = \text{Annual salary package} \times \frac{\text{Weeks spent on project}}{\text{52 weeks}} \times \text{percentage of time spent on project}$$

- Evidence may include:
    - staff details (name, title, function, FTE commitment), and
    - employment contracts, pay slips, and ATO payment summaries.

Contract expenditure

- Contract expenditure covers costs of agreed project activities undertaken by external contractors or service providers.

- All contractors must have a written agreement in place before work commences (e.g., contract, letter of engagement, or purchase order).
- Contracts must specify the nature of work, deliverables, fees or hourly rates, and any associated costs.
- Invoices must include:
    - a detailed description of work completed,
    - time spent or quantities delivered, and
    - relevant expenses or materials charged.
- Contracted work must be directly linked to approved project activities and represent reasonable market value.
- Applicants must retain records of contractor costs and payments, including:
    - contracts or letters of agreement,
    - purchase orders or supply agreements, and
    - invoices and payment confirmations.
- Biointelect Venturer may request these records at any time; if adequate evidence cannot be provided, the expense may be deemed ineligible.

Overseas expenditure

- The majority of project activities and expenditure are expected to take place within Australia. Applicants may seek funding for specific project components to be conducted overseas only when the necessary equipment, expertise, or resources are unavailable in Australia, and the activity is essential to achieving the project's objectives. Any overseas expenditure must first be approved by Biointelect Venturer for it to be considered an eligible expense.

Other Eligible Expenditure

Costs directly related to the project activity that are not already being supported through any other sources, or where other Commonwealth, state or territory governments do not have primary responsibility, including:

- Financial auditing of project expenditure,
- Costs you incur in order to obtain ethics and regulatory approvals during the project period. However, associated fees paid to the Commonwealth, state, territory and local governments are not eligible,
- Insurances which are specifically required to cover the grant activity, and/or
- Accessing expertise that supports the protection of IP.

Ineligible Expenditure

This section provides guidance on what is considered ineligible expenditure. Examples of ineligible expenditure include:

- Patent filing
- Maintenance or upgrades on buildings or structures,
- Activities, equipment or supplies that are already being supported through other sources or where other Commonwealth, state or territory governments have primary responsibility,

- Reimbursement of activities that have commenced prior to the execution of a grant agreement,
- Costs incurred prior to the project (Activity) start date,
- Retrospective costs,
- Any in-kind contributions
- Financing costs, including interest,
- Debt financing,
- Costs related to obtaining resources used on the project, including interest on loans, job advertising and recruiting, and contract negotiations,
- Non-project related staff training and development costs,
- Costs related to preparing the grant application, preparing any project reports (except costs of independent audit reports we require) and preparing any project variation requests,
- Conference attendance, and associated travel (except in pre-approved circumstances where the research outputs of the activity are to be presented),
- Health insurance, travel insurance, foreign currency, airport and related travel taxes, passports and visas,
- Entertainment and hospitality costs,
- Personal subscriptions (e.g., personal journal subscriptions),
- Personal membership of professional organisations and groups,
- Airline club membership,
- Communications costs (mobiles, telephone calls)
- Institutional overheads and administrative costs.

This list is not exhaustive and applies only to the expenditure of the grant funds. Other costs may be ineligible where we decide that they do not directly support the achievement of the planned outcomes for the project or that they are contrary to the objective of the grant opportunity.

Applicants must ensure they have adequate funds to meet the costs of any ineligible expenditure associated with the project.